Reviewed by Julian Douwes M.D., Chief Medical Officer, Klinik St. Georg
Antibiotics are the foundation of Lyme disease treatment and the standard of care for acute infection. For many patients, prompt antibiotic therapy leads to full recovery. For others, particularly those with chronic or late-stage disease, the picture is more nuanced. This page offers a balanced, evidence-based assessment of what antibiotics can and cannot do.
For acute Lyme: Antibiotics are highly effective when administered early. Standard treatment with doxycycline, amoxicillin, or cefuroxime resolves the infection in the majority of patients diagnosed within weeks of a tick bite.
For chronic Lyme: The effectiveness of antibiotics as a sole therapy is less clear. Some patients with persistent symptoms after standard treatment do not improve with additional antibiotic courses, suggesting that other factors beyond active bacterial infection may be driving their illness.
Within integrative protocols: Antibiotics remain an important component of multimodal treatment programs, particularly when timed to coincide with hyperthermia sessions (antibiotic-augmented thermotherapy), which may enhance their penetration and efficacy.
When Lyme disease is caught early, antibiotic therapy is the right treatment. This is not a matter of debate. The evidence is clear, the guidelines are well-established, and the outcomes are favorable.
First-line treatment for early localized Lyme disease (typically presenting with an erythema migrans rash and/or flu-like symptoms within days to weeks of a tick bite) follows well-established protocols:
For early disseminated Lyme disease with neurological involvement (such as facial nerve palsy or meningitis) or cardiac involvement (Lyme carditis with significant conduction abnormalities), intravenous ceftriaxone is the standard approach, typically administered for 14–28 days.
Success rates for early treatment are high. Studies consistently show that the majority of patients treated with appropriate antibiotics during the early stage of Lyme disease make a full recovery. Early diagnosis and prompt treatment remain the single most important factor in Lyme disease outcomes.
This is why we strongly encourage anyone with a known tick bite, an erythema migrans rash, or acute symptoms consistent with early Lyme disease to seek immediate medical attention and begin antibiotic therapy without delay.
The conversation becomes more complex when we discuss patients who continue to experience significant symptoms despite having received standard antibiotic treatment, or who were not diagnosed and treated until months or years after the initial infection.
This is where honest assessment matters more than advocacy for any particular position.
What the evidence suggests. An estimated 10–20% of patients treated for Lyme disease with standard antibiotic regimens continue to experience symptoms such as fatigue, musculoskeletal pain, and cognitive difficulties for months or years afterward. This phenomenon is sometimes called Post-Treatment Lyme Disease Syndrome (PTLDS). For patients never adequately treated in the acute phase, the rates of persistent symptoms may be significantly higher.
The medical debate. There is genuine disagreement in the medical community about why these symptoms persist and what to do about them. Some authorities hold that persistent symptoms after treatment reflect post-infectious immune dysregulation, not active ongoing infection, and that additional antibiotics are therefore unlikely to help. Others argue that Borrelia can persist in certain tissue compartments despite standard antibiotic courses and that ongoing or alternative antimicrobial strategies may be warranted.
What both sides agree on. Both perspectives acknowledge that a significant number of patients suffer genuinely debilitating symptoms after standard Lyme treatment, and that current treatment approaches do not adequately serve this population.
Without dismissing the value of antibiotics, there are biological reasons why they may be insufficient as a sole therapy for patients with chronic or late-stage Lyme disease:
Borrelia morphological variants. Borrelia burgdorferi does not exist exclusively in the spirochetal (spiral) form that antibiotics target most effectively. Research has demonstrated that Borrelia can transition to round body (cyst) forms and aggregate in biofilm communities. These alternative forms show reduced susceptibility to many standard antibiotics in laboratory studies. While the clinical significance of these findings is still being investigated, they may partially explain treatment failures.
Tissue sequestration. Borrelia has been shown to cross the blood-brain barrier, persist in collagen-rich tissues such as joints and tendons, and survive within cells. Achieving adequate antibiotic concentrations in all of these compartments simultaneously is pharmacologically challenging, particularly with oral formulations.
Immune dysregulation. Chronic Borrelia infection can trigger immune changes that persist even after the bacterial load is reduced. Elevated inflammatory cytokines, autoimmune-like antibody production, and disrupted T-cell function can all continue to drive symptoms independently of active infection. Antibiotics do not directly address these immune mechanisms.
Microbiome disruption. Prolonged antibiotic courses, particularly broad-spectrum regimens, significantly disrupt the gut microbiome. Given the established links between gut health, immune function, and neurological health, extended antibiotic use can create secondary problems that compound the original symptoms.
Co-infections. Tick-borne co-infections such as Babesia, Bartonella, and Ehrlichia require different antimicrobial agents than Borrelia. If co-infections are not identified and specifically addressed, treatment focused only on Borrelia will leave other pathogens untreated, and symptoms will persist.
None of these points are arguments against antibiotics. They are arguments for understanding the limitations of any single therapeutic approach when dealing with a complex, systemic infection.
At Klinik St. Georg, antibiotics are not discarded. They are used strategically, as one component of a multimodal treatment program. The key difference is how and when they are administered.
Antibiotic-augmented thermotherapy. When antibiotics are administered in conjunction with whole-body hyperthermia, several factors change in their favor. Elevated core temperature increases blood flow and tissue perfusion, potentially improving antibiotic distribution to compartments that are poorly reached at normal body temperature. Heat stress also increases bacterial metabolic activity, which can make dormant or slow-growing organisms more susceptible to antimicrobial agents. And the direct thermal effect on Borrelia's structural integrity may lower the threshold for antimicrobial killing.
This combined approach does not replace antibiotics. It enhances them by addressing the pharmacokinetic and biological limitations that may cause them to fail when used alone.
Targeted selection based on diagnostics. Rather than empiric treatment with a single antibiotic, the integrative protocol begins with comprehensive diagnostic testing, including co-infection panels. Antimicrobial agents are then selected based on identified pathogens and their known susceptibilities. This may include combinations of antibiotics, antifungals, and antiparasitic agents, each targeting a specific component of the patient's infection profile.
Supported by adjunctive therapies. Within the integrative program, antibiotic therapy is complemented by immune support, detoxification protocols to manage Herxheimer-like reactions, and probiotic support to mitigate microbiome disruption. These adjunctive measures help patients tolerate treatment better and may improve overall outcomes.
We believe honesty serves patients better than advocacy.
Antibiotics work. For acute Lyme disease, they are the most important intervention available. If you have recently been bitten by a tick and suspect early Lyme disease, please see a physician and begin antibiotic treatment promptly. Do not delay in favor of any alternative approach.
Antibiotics may not be enough. For patients with chronic, persistent, or late-diagnosed Lyme disease, antibiotics alone have a documented track record of incomplete resolution. This is not a failure of antibiotics. It is a reflection of the complexity of chronic tick-borne illness.
The answer is not less treatment or more of the same treatment. It is more comprehensive treatment, addressing the multiple dimensions of chronic Lyme disease simultaneously: the infection, the immune dysfunction, the inflammatory burden, and the systemic consequences that have accumulated over months or years of illness.
If you are currently receiving antibiotic treatment for Lyme disease and it is working, that is genuinely good news. Continue with your physician's guidance. If you have been through multiple rounds of antibiotics without adequate improvement, it may be worth exploring whether a multimodal approach could address the aspects of your illness that antibiotics alone have not resolved.
We respect the role of antibiotics in Lyme treatment. We also recognize their limitations in chronic disease. Our goal is not to replace one approach with another, but to build a more complete one.
No. Never discontinue prescribed medication without consulting your physician. If you are considering additional treatment options, discuss this with your current doctor and, if appropriate, with our medical team during a consultation. Changes to your antibiotic regimen should always be medically supervised.
Prolonged antibiotic use carries documented risks, including microbiome disruption, antibiotic resistance, gastrointestinal complications, and in some cases, organ toxicity. These risks must be weighed against potential benefits in each individual case. This is one reason why exploring adjunctive and alternative approaches may be valuable for patients who have not responded to standard antibiotic courses.
Yes. Antibiotics are an integral part of the integrative protocol when clinically indicated. The difference is that they are used strategically, in combination with hyperthermia and other modalities, rather than as a standalone therapy. The specific agents, dosing, and timing are individualized based on diagnostic findings.
Some patients incorporate herbal antimicrobials such as Japanese knotweed, cat's claw, or cryptolepis into their treatment. While preliminary research suggests certain herbal compounds may have activity against Borrelia, the evidence base is substantially smaller than for pharmaceutical antibiotics. We recommend discussing any herbal protocols with your medical team to ensure they do not conflict with other treatments.
How antibiotics, hyperthermia, apheresis, and immune support come together in one coordinated treatment protocol.
How whole-body hyperthermia targets Borrelia at the temperature threshold where it becomes structurally unstable.
Understanding why some patients develop persistent symptoms and what the current science says about chronic Lyme.
If antibiotics have not been enough, a consultation can help clarify what else might be contributing to your symptoms and whether a multimodal protocol could help.
Request a case review